Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 known ✓ | P47900 | 10/20 | 0.66 |
| ▸ | P2RY2 known ✓ | P41231 | 3/20 | 0.61 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.61 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.61 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.61 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.66 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | SRC | P12931 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.61 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.61 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.61 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.61 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1526121 | 0.93 | P2RY1 (0.66) | P2RY1P2RY11ENPP1P2RY2SRC | |
| SCHEMBL22099721 | 0.90 | P2RY1 (0.69) | P2RY1P2RY11ENPP1TSHRKDM4E | |
| SCHEMBL29354292 | 0.89 | P2RY1 (0.77) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Adenosine Phosphate SCHEMBL2828289 | 0.88 | P2RY1 (0.76) | P2RY1P2RY11ENPP1P2RY2SRC | |
| SCHEMBL29389326 | 0.88 | P2RY1 (0.75) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| Potassium Ion SCHEMBL9616871 | 0.88 | P2RY1 (0.63) | P2RY1P2RY11ENPP1TSHRKDM4E | |
| SCHEMBL375102 | 0.86 | RNASEL (0.61) | P2RY1P2RY11ENPP1P2RY2SRC | |
| SCHEMBL8508626 | 0.85 | P2RY1 (0.63) | P2RY1P2RY11ENPP1P2RY2SRC | |
| Adenosine Triphosphate SCHEMBL985843 | 0.84 | P2RY1 (0.71) | P2RY1P2RY11P2RY2SRCSMN1; SMN2 | |
| SCHEMBL4329344 | 0.84 | RNASEL (0.55) | P2RY1P2RY11ENPP1P2RY2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091249-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | INVIRSA, INC. (US) | 2024-03-21 | — | — | US | disclosed |
| US-11857561-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | INVIRSA, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230414647-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | INVIRSA, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| US-11793826-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | INVIRSA, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4226971-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | Invirsa, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3773604-B1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | INVIRSA INC (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-3978003-A1 | MEDICAL USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | Invirsa, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20220054522-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | INVIRSA, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3416654-B1 | MEDICAL USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | INVIRSA INC (US) | 2021-10-27 | — | — | EP | disclosed |
| US-11110112-B2 | Methods for the use of 5'-adenosine diphosphate ribose (ADPR) | INVIRSA, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210161936-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | INVIRSA, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-10946034-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | INVIRSA, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200330498-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | Invirsa, Inc (US) | 2020-10-22 | — | — | US | disclosed |
| US-20190298752-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | INVIRSA, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| EP-3416654-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | Invirsa, Inc. (US) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017143113-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | INVIRSA, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190298752-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | SIRT6, ADAR, SIRT1 | P2RY1 342/4885P2RY2 532/4885ADORA1 157/4885 |
| US-11110112-B2 | Methods for the use of 5'-adenosine diphosphate ribose (ADPR) | ADAR, CD38, PARP1 | P2RY1 51/4885P2RY2 89/4885ADORA1 22/4885 |
| US-10946034-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | SIRT6, ADAR, SIRT1 | P2RY1 357/4885P2RY2 552/4885ADORA1 168/4885 |
| US-11793826-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | SIRT6, ADAR, SIRT1 | P2RY1 357/4885P2RY2 552/4885ADORA1 168/4885 |
| US-11857561-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | ADAR, CD38, PARP1 | P2RY1 54/4885P2RY2 91/4885ADORA1 22/4885 |
| US-20210161936-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | SIRT6, ADAR, SIRT1 | P2RY1 342/4885P2RY2 532/4885ADORA1 157/4885 |
| US-20230414647-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | SIRT6, ADAR, SIRT1 | P2RY1 342/4885P2RY2 532/4885ADORA1 157/4885 |
| US-20240091249-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | ADAR, CD38, PARP1 | P2RY1 51/4885P2RY2 89/4885ADORA1 22/4885 |
| US-20220054522-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | ADAR, CD38, PARP1 | P2RY1 51/4885P2RY2 89/4885ADORA1 22/4885 |
| US-20200330498-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | ADAR, CD38, PARP1 | P2RY1 51/4885P2RY2 89/4885ADORA1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.